Galmed Pharmaceuticals Ltd. Stock
Pros and Cons of Galmed Pharmaceuticals Ltd. in the next few years
Pros
Cons
Performance of Galmed Pharmaceuticals Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd. | 0.570% | 3.315% | 6.250% | 21.429% | -14.220% | - | - |
| Oramed Pharmaceuticals | -2.360% | 0.971% | 0.660% | -20.638% | 8.129% | -72.987% | -21.965% |
| Enlivex Therapeutics Ltd. | 1.570% | -8.276% | -1.481% | -46.800% | -40.625% | -81.655% | - |
| Evolus Inc | -1.680% | -4.132% | 4.505% | 26.087% | 28.177% | 57.823% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Galmed Pharmaceuticals (GMED), a company operating within the Biotechnology & Medical Research industry, it's evident that the organization faces some challenges. This analysis will provide a detailed overview of the company's financials, highlighting both positive and negative aspects to give a comprehensive understanding of GMED's current financial position.
Strong Liquidity Position: Galmed has maintained a robust liquidity position over the years, with a considerable amount of cash and short-term investments in its balance sheets. This strong liquidity indicates that the company has adequate funds to cover its short-term obligations and can invest in growth opportunities.
Decreasing Total Liabilities: The company's total liabilities have shown a decreasing trend over the past few years, which is a positive sign. A reduction in liabilities indicates better debt management and lower financial risk.
Comments